Neurizon

🎉 PharmAust Changes Name to Neurizon Therapeutics! 🎉 Embracing our mission to accelerate the development of neurodegenerative treatments and bring a promising new horizon to patients. 🌅 #NeurizonTherapeutics #ALS #NeurodegenerativeResearch

Neurizon has entered into a global license agreement with Elanco Animal Health — a strategic step that strengthens our regulatory and manufacturing foundation for NUZ-001 and accelerates our path toward global commercialisation. investorhub.neurizon.com/announcements/…

European Medicines Agency (EMA) has issued a positive opinion on Orphan Medicinal Product Designation (OMPD) for our lead ALS drug candidate, NUZ-001. Read the full announcement here: investorhub.neurizon.com/announcements/…

Neurizon Therapeutics is partnering with GenieUs Genomics to leverage advanced genomic profiling in our Phase 1 MEND study of NUZ-001, to better understand how patients respond to our ALS drug candidate Read the full press release from GeniUs Genomics at: einpresswire.com/article/757429…

We are pleased to share Neurizon Therapeutics’ Quarterly Activity Results, highlighting our continued progress in advancing treatments for ALS and other neurodegenerative diseases. Visit our Investor Hub to read the full announcement at: lnkd.in/e6gnnQjH

🌟 Exciting news from #Neurizon! We've just presented our Phase 1 MEND study data at the 2024 #NEALS Meeting. Key findings: safety, tolerability, and significant survival benefits in #ALS patients with NUZ-001. #Biotech #ALSResearch #Innovation

💰 PharmAust (ASX: PAA) secures an $887K rebate under Australia’s R&D Tax Incentive, boosting resources for our ALS research and monepantel development! Further rebate expected soon to support our Phase 2/3 trials. #Biotech #ALSResearch #PharmAust

📎PharmAust submits Orphan Medicinal Product Designation request to EMA for monepantel, targeting ALS! If granted, this would provide regulatory support & 10 years of EU market exclusivity. Decision expected in Dec 2024. Exciting times ahead! 🌍 #PharmAust #Biotech #ALS

📢 PharmAust is thrilled to share an exclusive interview with Dr. Michael Thurn ahead of our participation at the Spark+ Australian Equities Day in Singapore on Sept 20! 🔗 Watch the full interview & register: linkedin.com/feed/update/ur…

Exciting to see The Australian feature Pharmaust in an article about our recent Morgans coverage! 🚀 The potential upside for monepantel is gaining recognition. Check out the full story in The Australian: theaustralian.com.au/business/stock… #Pharmaust #Biotech #ALS #TheAustralian

Excited to see Dr. Susan Mathers present the promising Phase 1 results of monepantel in ALS patients at the MND Research Symposium in Melbourne. A crucial step forward in improving lives worldwide! 🌍🔬 #ALS #MND #Research #Pharmaust

PharmAust’s breakthrough drug monepantel is generating buzz with its promising results in treating MND/ALS, potentially transforming the future for patients and offering investors a lucrative opportunity. buff.ly/4cIwPtO @PharmAust #ASX $PAA

🚀 Excited to launch our new podcast, "Neural Threads"! 🧬 Hosted by CSO Nicky Wallis, dive into the latest in biotech with a focus on neurodegenerative diseases & innovative therapies. youtube.com/watch?v=u-oLwD…

PharmAust has released promising interim results from its ongoing open-label extension study of its lead drug monepantel to treat Amyotrophic Lateral Sclerosis. buff.ly/3AIZAcA @PharmAust #ASX $PAA

PharmAust announces positive interim results from the Open-Label Extension study in ALS! 4 months of monepantel treatment shows promising survival benefits and slowed disease progression. We're committed to advancing this crucial research. #ALS #biotech #innovation

PharmAust (ASX: PAA) is featured in Stockhead's Health & Biotech Investor Guide FY2025! 🌟 Proud to be recognized among top healthcare innovators. Dive into the guide to learn more about our journey and future prospects. 📈🔬 #PharmAust #Biotech #ALS #Healthcare #ASX

PharmAust presented at the Techknow Invest Roadshow! 🚀🎤 Check out our presentation on advancing ALS/MND treatments with monepantel. Watch here: youtube.com/watch?v=2zh9wJ…

🌟 Exciting News! Join PharmAust at the TechKnow Invest Roadshow in Sydney on July 30th and Melbourne on July 31st. Connect with industry leaders in the tech and medtech sectors. Don't miss out! 🚀 #TechKnow2024 #PharmAust #MedTech